Online inquiry

IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6019MR)

This product GTTS-WQ6019MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL12B gene. The antibody can be applied in Psoriatic arthritis (PSA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002187.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3593
UniProt ID P29460
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6019MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2432MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 145
GTTS-WQ10438MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ2261MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ7718MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ7838MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ14312MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ4805MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BT 5/9
GTTS-WQ9964MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA KBSA301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW